Home Drug Guide Bevacizumab-awwb

Drug Guide

Generic Name

Bevacizumab-awwb

Brand Names Mvasi

Classification

Therapeutic: Antineoplastic agent

Pharmacological: Monoclonal antibody (vascular endothelial growth factor inhibitor)

FDA Approved Indications

Metastatic colorectal cancer
Non-squamous non-small cell lung cancer
Glioblastoma (recurrent) Monitor the official FDA label for the most current approved indications as they may expand or change.

Mechanism of Action

Bevacizumab-awwb binds to vascular endothelial growth factor A (VEGF-A), preventing it from activating VEGF receptors on the surface of endothelial cells, thereby inhibiting angiogenesis necessary for tumor growth.

Dosage and Administration

Adult: Administer as an infusion at the recommended dosage (e.g., 5-15 mg/kg every 2-3 weeks), depending on the specific indication and protocol.

Pediatric: Use is generally limited; consult specific guidelines for pediatric dosing.

Geriatric: No specific adjustments provided; consider increased risk of adverse effects in elderly.

Renal Impairment: No specific dose adjustment indicated; monitor closely.

Hepatic Impairment: No specific dose adjustment indicated; use with caution.

Pharmacokinetics

Absorption: Not applicable (administered IV).

Distribution: Extensively distributed in the vascular and extracellular compartments.

Metabolism: Broken down by proteolytic enzymes into small peptides and amino acids.

Excretion: Eliminated via catabolism; not through urine or feces.

Half Life: Approximately 20 days (varies).

Contraindications

Known hypersensitivity to bevacizumab, other humanized monoclonal antibodies, or excipients.

Precautions

Risk of bleeding, hypertension, impaired wound healing, gastrointestinal perforation, and wound dehiscence.
Use with caution in patients with prior wound healing complications or recent surgery.
Monitor blood pressure and for signs of bleeding or thromboembolism.

Adverse Reactions - Common

Hypertension (Common)
Proteinuria (Common)
Fatigue (Common)
Diarrhea (Common)

Adverse Reactions - Serious

Gastrointestinal perforation (Rare)
Hemorrhage (including major bleeding) (Rare)
Wound healing complications (Rare)
Thromboembolism (Rare)
Hypertensive crisis (Rare)

Drug-Drug Interactions

Other agents that increase bleeding risk, anticoagulants, antiplatelet agents.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor blood pressure, renal function, and signs of bleeding or wound healing issues.

Diagnoses:

Risk for bleeding
Impaired skin integrity
Ineffective tissue perfusion.

Implementation: Administer IV infusion as ordered, monitor infusion site and patient response, assess for adverse effects.

Evaluation: Monitor for expected therapeutic effects and adverse reactions; adjust therapy as needed.

Patient/Family Teaching

Report any signs of bleeding, unusual pain, or wound issues immediately.
Monitor blood pressure regularly.
Avoid invasive procedures or trauma when possible.

Special Considerations

Black Box Warnings:

Gastrointestinal perforation, wound healing issues, hemoptysis, and severe bleeding.
Risk of arterial thromboembolic events.

Genetic Factors: None specific.

Lab Test Interference: Can cause proteinuria, monitor with urinalysis.

Overdose Management

Signs/Symptoms: Bleeding, hypertension, or infusion reactions.

Treatment: Supportive care, maintain airway, breathing, and circulation; manage symptoms accordingly.

Storage and Handling

Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F).

Stability: Stable for up to 24 hours at room temperature during administration; follow manufacturer guidelines.